News

September 19, 2016

FierceBiotech Names Rhythm as a “Fierce 15” Biotechnology Company of 2016

July 27, 2016

Rhythm Announces “The Genetic Obesity Project” to Expand Understanding of Rare Genetic Disorders of Obesity

July 20, 2016

Rhythm Announces New England Journal of Medicine Publication of Setmelanotide Phase 2 Data for Treatment of POMC Deficiency Obesity

January 7, 2016

Rhythm Receives FDA Breakthrough Therapy Designation for Setmelanotide for Treatment of POMC Deficiency Obesity

January 7, 2016

Rhythm Receives Orphan Drug Designation for Setmelanotide for the Treatment of Prader-Willi Syndrome

January 5, 2016

Rhythm and Camurus Announce License Agreement for Extended Release FluidCrystal Setmelanotide

December 11, 2014

Rhythm Appoints Fred T. Fiedorek, M.D., Chief Medical Officer

June 23, 2014

Rhythm Presents Clinical Data that RM-493 Increases Energy Expenditure in Obesity Study

September 24, 2013

Rhythm Initiates Clinical Trial of RM-493 for Obesity Caused by Genetic Variant

January 4, 2013

Rhythm Initiates Phase 2 Clinical Trial of RM-493 for Obesity